

Role of GeMCRIS in the Recombinant DNA Advisory Committee Safety Oversight

2000-2001: NIH Enhances Oversight

- Series of NIH initiatives to enhance oversight
- Advisory Committee to the Director recommends enhancing the RAC protocol review process and optimizing analysis and communication of safety information
  - Amendments to the *NIH Guidelines*
  - NIH Gene Transfer Safety Assessment Board
  - National database
  - National Safety Symposia

The RAC and Safety Oversight

- **Appendix M Reporting Requirements**
  - **Mandates reporting of adverse events to OBA**
  - **Designation of subgroup of the RAC to:**
    - **Review in closed session data on safety and toxicity across gene transfer trials**
    - **Identify significant trends or significant single reports**
    - **Report significant trend findings and aggregated trend data to the RAC**

Protocol Oversight

Genetic Modification Clinical Research Information System (GeMCRIS)

A public database of human gene transfer trials registered with the National Institutes of Health

http://www.gemcris.od.nih.gov

Development of GeMCRIS

- Steering Committee included all NIH ICs involved with Gene Transfer and the National Library of Medicine
- Developed in collaboration with FDA
- Implementation of a standard regulatory medical vocabulary (MedDRA)
- Genetic element vocabulary developed specifically for gene transfer research
- On-line adverse event reporting capability for Principal Investigators

GeMCRIS: Underlying Philosophy

A system that:

- Promotes public access to information and understanding about gene transfer research
- Facilitates investigator compliance with adverse event reporting
- Harmonizes NIH and FDA approaches to data collection
- Assists NIH in conducting oversight of human gene transfer trials

GeMCRIS

Genetic Modification Clinical Research Information System
Version 2.0

Home | Search | User Help

Support

- Feedback
- Frequently Asked Questions
- Contact Us
- Browser Requirements

Welcome to the NIH Genetic Modification Clinical Research Information System (GeMCRIS). GeMCRIS is a comprehensive information resource and analytical tool for scientists, research participants, institutional oversight committees, sponsors, federal officials, and others with an interest in human gene transfer research. GeMCRIS allows users to access an array of information about human gene transfer trials registered with the NIH, including medical conditions under study, institutions where trials are being conducted, investigators carrying out these trials, gene products being used, route of gene product delivery, and summaries of study protocols.

To facilitate access to this information, GeMCRIS offers a number of preformatted reports. You can also create your own query tailored to your particular information needs. To get started, use the "Search" menu item above, or click the "Frequently Asked Questions" link on the left to learn more about using the system.

We are seeking comments on GeMCRIS's utility and ease of use. Please take a moment to respond to the questions on the form provided through the "Feedback" link on this page. Your input is critical to ensuring that the system meets the needs of all its diverse users.

Related Information

- About The RAC
- NIH Guidelines
- Documents (With Quarterly Reports)

Site Map

GeMCRIS®

Genetic Modification Clinical Research Information System
Version 4.0

Home | Search | User Help

Search menu:
- Protocols
  - Search by Condition/Title
  - Search by Product
- Principal Investigators
- Vocabulary Reports

Support

- Feedback
- Frequently Asked Questions
- Contact Us
- Browser Requirements

...nical Research (GeMCRIS®). GeMCRIS is a comprehensive information resource and analytical tool for scientists, research participants, institutional oversight committees, sponsors, federal officials, and others with an interest in human gene transfer research. GeMCRIS allows users to access an array of information about human gene transfer trials registered with the NIH, including medical conditions under study, institutions where trials are being conducted, investigators carrying out these trials, gene products being used, route of gene product delivery, and summaries of study protocols.

To facilitate access to this information, GeMCRIS offers a number of preformatted reports. You can also create your own query tailored to your particular information needs. To get started, use the "Search" menu item above, or click the "Frequently Asked Questions" link on the left to learn more about using the system.

We are seeking comments on GeMCRIS's utility and ease of use. Please take a moment to respond to the questions on the form provided through the "Feedback" link on this page. Your input is critical to ensuring that the system meets the needs of all its diverse users.

Related Information

- About The RAC
- NIH Guidelines
- Documents (With Quarterly Reports)
- NGVL Pharm/Tox Database

Site Map

GeMCRIS®

Genetic Modification Clinical Research Information System
Version 4.0

Home | Search

- Protocols
- Principal Investigators
- Vocabulary Reports
  - Ex-Vivo Cell Vocabulary
  - Genetic Element Vocabulary
  - Vector Vocabulary
  - VPC Vocabulary
    - Term Report
    - Hierarchy Report

information resource and analytical tool for scientists, research participants, institutional oversight committees, sponsors, federal officials, and others with an interest in human gene transfer research. GeMCRIS allows users to access an array of information about human gene transfer trials registered with the NIH, including medical conditions under study, institutions where trials are being conducted, investigators carrying out these trials, gene products being used, route of gene product delivery, and summaries of study protocols.

To facilitate access to this information, GeMCRIS offers a number of preformatted reports. You can also create your own query tailored to your particular information needs. To get started, use the "Search" menu item above, or click the "Frequently Asked Questions" link on the left to learn more about using the system.

We are seeking comments on GeMCRIS's utility and ease of use. Please take a moment to respond to the questions on the form provided through the "Feedback" link on this page. Your input is critical to ensuring that the system meets the needs of all its diverse users.

Support

- **Feedback**
- **Frequently Asked Questions**
- **Contact Us**
- **Browser Requirements**

Related Information

- **About The RAC**
- **NIH Guidelines**
- **Documents (With Quarterly Reports)**
- **NGVL Pharm/Tox Database**

Site Map

Publicly Available Protocol Information

- Protocol title
- Study phase
- Clinical indication(s)
- Investigator(s)
- Clinical trial site(s)
- Scientific abstract
- Non-technical abstract
- Vector
- Transgene
- Route of administration
- Link to *Clinical Trials.Gov*

Serious Adverse Event Reporting

Tools for streamlined and effective communication and analysis of safety data

- **One AE reporting format**
  - Copies can be sent to FDA, IRB, IBC
- **Uniform “Core” data elements**
- **Controlled medical vocabularies**
- **On-line adverse event reporting**

Adverse Event Reports: Core Data Elements

- Date and description of event
- Seriousness and severity
- Suspected cause(s)
- Attribution (gene transfer product, underlying disease)
- Relevant clinical observations and history
- Description of gene transfer product
- Route and site of administration
- Dosing information

GeMCRIS® Genetic Modification Clinical Research Information System Version 4.0

Home | AE Reporting | Search | User Help

- **Adverse Event Report**
  - Product Dosings
  - Lab Test Results
  - Medical Conditions
  - Concomitant Medications
  - Contributing Factors
  - Adverse Event Terms
  - Attributions

New Adverse Event Report

Fields marked with * are required.

OBA Protocol Number: 999
Protocol Title: IBC123- A Phase I Clinical Trial to evaluate multiple injections of CI-1023 for treatment of Achilles tendonitis.

Report Information

Sponsor Protocol Number:

Long Term Study Number (if applicable): --Select--

Adverse Event Seriousness Description: * --Select--

Seriousness: * --Select-- Expectedness: * --Select-- Relatedness: * --Select--

Note: If you cannot rule out study agent causality, then select 'Related' and explain in the report.

AER Type: Initial AER Follow-Up Number: 0

AER Ticket Number: (Will be generated automatically)

Investigator Information

Investigator: --Select-- Search

Last Name: * First Name:

Phone Number [(xxx) xxx-xxxx]: ext:

Organization:

Foreign Phone Number: E-Mail Address:

Reporter Information

Reporter: --Select-- Search

Last Name: * First Name:

Phone Number [(xxx) xxx-xxxx]: ext:

Although this field is not required, it is important to include a phone number so that OBA can quickly contact you in case questions exist about your submission.

Foreign Phone Number: E-Mail Address:


Adverse Event Report
Product Dosings
Lab Test Results
Medical Conditions
Concomitant Medications
Contributing Factors
Adverse Event Terms
Attributions
View Current
Edit Adverse Event Report
Fields marked with * are required.
OBA Protocol Number: 1
Protocol Title: The Treatment of Patients with Advanced Cancer Using Cyclophosphamide, Interleukin-2 and Tumor Infiltrating Lymphocytes.
Report Information
IND Number: * IND001 -- Primary
Sponsor Protocol Number:
Long Term Study Number (if applicable): --Select--
Adverse Event Seriousness Description: * Initial or prolonged hospitalization
--Select--
Death
Life threatening
Initial or prolonged hospitalization
Disability
Congenital anomaly
Required intervention to prevent permanent impairment/damage
Other medically important condition
Not Serious
Seriousness: * Serious
Expect
Note: If you cannot rule out study agen
AER Type: Follow-Up
AER Ticket Number: GC1
Investigator Information
Investigator: doctor, doctor -- National Cancer Institute - NIH
Search
Last Name: * doctor
First Name: doctor
Phone Number [(xxx) xxx-xxxx]:
ext:

GeMCRIS Adverse Event Report

Report Generated 05/08/2007 02:31 PM

Part I - Adverse Event Report Identification Information	
IND Number	10036
OBA Protocol Number	999
Sponsor Protocol Number	IBC123 (Collected: 1111)
Protocol Title	IBC123- A Phase I Clinical Trial to evaluate multiple injections of CI-1023 for treatment of Achilles tendonitis.
AER Category	C1 -- Serious/unrelated/unexpected
AER Date	10/16/2006
AER Receipt Date	10/16/2006
RAC Review Date	03/06/2007
AER Ticket Number	GC8295, Initial
OfficEdge Document Number	756
AER Status	Submitted
AER Source	NIH (Originating Source: Sponsor)
Investigator/Reporter selected from drop list?	Yes/Yes
Administrative Notes	
Medical Officer Review	Not Yet Reviewed
Created	By Maureen Montgomery on 10/16/2006 at 11:25 AM
Last Updated	By Jacqueline Curay on 05/07/2007 at 10:11 AM

Part II - Subject Information	
Subject ID	4444
Subject Birth Date	01/04/1958
Subject Gender	Male
Weight / Height	200 pounds / 65 inches
Was a Study Agent Administered?	Yes
Treatment Group	
Concomitant Medications	atenolol - Tenormin HCTZ hydrochlorothiazide - Esidrix, HydroDiuril, Oretic, Ezide, Microzide, Hydro-Par, generics terazosin - Hytrin, various generics

Part II(a) - Reported Medical Conditions

Condition Name	Other Condition Name	Condition Category	Currently Active Condition	Condition Description
*Other Medical Condition (describe)	Achilles Tendinitis	Target Disease		
BPH Benign prostatic hypertrophy		Other Condition		
Hypercholesterolemia		Other Condition		

Part III - Adverse Event Information

Adverse Event Date	10/16/2006
Adverse Event Description	Subject was dosed with gene product on 10/07/06. One week later developed swelling in right leg above injection site and pain. Subject admitted to excessive dancing night prior to developing pain. Subject seen in ER. Doppler equipment not available so subject admitted for observation. DVT ruled out by doppler and subject discharged next day. Event resolved.
Adverse Event Web Summary	Subject admitted with pain and swelling in leg one week after injection. DVT ruled out and subject discharged.
Adverse Event Seriousness Description	Initial or prolonged hospitalization
Outcome	Recovered/Resolved
Subject Death Date	
Autopsy Performed?	
Summary of All Relevant Tests	D-Dimer 250 Lower Extremity Doppler
Summary of Adverse Event Treatments	Lovenox Tylenol
Other Documents to Be Submitted	
Contributing Factors	

Part III(a) - Protocol Exemptions/Deviations

Exemption/Deviation Occurred?	
Description of Exemption/Deviation	
Exemption/Deviation Categories	

Part III(b) - Reported Quantitative Lab Test Results

Test Name	Baseline Date	Baseline Value	Worst Date	Worst Value	Recovery Date	Recovery Value	Reference Min Value	Reference Max Value
No information registered for this section of the AE report.								

Part III(c) - Reported Microbiology Lab Test Results

Lab Test Name	Date	Test Performed	Results

Part III(e) - Reported Adverse Event Terms

Term	Severity	Date First Observed	End Date
Pain - Extremity-limb	Moderate Reaction		

Part IV - Gene Transfer Product Dosing

Gene Transfer Product Name	AdgvVEGF121.10
Lot Number	
Manufactured at NGVL?	
Date of first exposure to study agent	09/01/2006
Date of last exposure prior to event	10/07/2006
Number of Courses Prior to Event	
Last Dosage Received	$5 * 10^5$
Total dosage received prior to event	$1.5 * 10^6$
Unit of Measure	pfu
Number of Doses on Last Course	
Route/Site of Administration	Intramuscular -- Other (specify)
Site of Administration	
Administration Stopped Because of the Adverse Event	

Part V - Attributions

Pain - Extremity-limb (Source: Principal Investigator)

	Unrelated	Unlikely	Possible	Probable	Definite
Contributing Factors					
Physical Activity				X	
Products					
AdgvVEGF121.10	X				
Medical Conditions					
*Other Medical Condition (describe) -- Achilles Tendinitis			X		
BPH Benign prostatic hypertrophy	X				
Hypercholesterolemia	X				
Routes of Administration					
Intramuscular			X		

Part VI - Investigator/Reporter Information

Investigator	investigator trimmer, Bethesda Achilles Institute

What Do I Get out of Using GeMCRIS?

- Instantaneous reporting
- Control over the database entry
- Drop down menus to facilitate data entry
- Ability to edit reports “in progress”
- Format is harmonized with FDA requirements
- Ability to print or save in PDF format for submission to FDA, IBC, IRB
- Electronic record of submissions

PROTOCOL AND EVENT TYPE	
NIH/OBA (RAC) Protocol Number	
FDA IND number	
Date this report completed:	
Seriousness of the AE (choose one)	Death Life-threatening Initial or prolonged hospitalization Disability Congenital anomaly Required intervention to prevent permanent impairment/damage Other medically important condition Non-serious
Severity of Event	Minimal Moderate Severe Life- Threatening Fatal
Was this event expected in terms of its severity?	Yes No
Was this event expected in terms of its specificity?	Yes No
Relationship of Event to gene transfer product	Unrelated Unlikely Possible Probable Definite
Attribution of AE Attribution of AE, continued	Concomitant medication Product Intervention Underlying disease Route of administration Other suspected cause (describe)
Type of report	Initial Follow-up
DEMOGRAPHICS	
PI Name	
Name of Clinical Trial Site/Organization	
PI Telephone Number	
PI E-mail Address	
Reporter name	
Reporter Telephone number	
Reporter E-mail address	

Research Participant's study identification number	
Research Participant's gender	
Research Participant's date of birth	
Research Participant's date of death	
Research Participant's weight in kgs	
Research Participant's height in cms	
Which Arm/Cohort/treatment group was the subject assigned to?	
Was subject dosed?	Yes No Information Not Available
What study agent was received:	IND agent Placebo Blinded Study Agent
Were there any Protocol Deviations/Violations/Exceptions for this participant?	Yes:_____ _____ _____ No

DETAILED ADVERSE EVENT INFORMATION

Adverse Event Date	
Description of Event	
Relevant tests (e.g. x-rays) and results	
Treatment (s) of Adverse Event (Include medications used to treat this event.)	
Name of Concomitant Medications (Do not include medications used to treat this event.)	
Pre-existing conditions/ relevant clinical history (if this is an oncology trial, please designate primary disease, e.g. ovarian cancer)	
Date(s) of treatment(s) of the adverse event	

Was autopsy performed?	Yes No
Date of autopsy	_____ or Not Applicable _____
Outcome of the event	Recovered/resolved Recovering/resolving Not recovered/not resolved Recovered/resolved with sequelae Fatal Unknown
Documentation accompanying the report (e.g., H& P, Progress Notes, Discharge Summary, Lab or Autopsy Reports, Other, etc.)	
Description of any "other" documentation	
PRODUCT AND DOSING INFORMATION	
Name of gene transfer product	
Vector type (e.g. adenovirus)	
Vector sub-type (e.g. type 5, also include relevant deletions)	
Lot number	
Was the agent manufactured at an NGVL?	
Route of administration	
Site of administration	
Did subject receive the dose specified in the protocol?	
If not, what dose was given?	
Date of first exposure to study agent?	
Date of most recent exposure to study agent?	
Total dose received prior to this event?	
Total dose quantity administered to subject to date	
Unit of measure for a single dose	
Dose quantity in a single administration	
If courses used, how many were given prior to this event?	
How many doses on the last course were given?	
Was the administration of this product stopped because of this adverse event?	

Serious AE Reports



Serious, possibly related and unexpected

Recombinant DNA and Gene Transfer

Office of Biotechnology Activities

NSABB
GeMCRIS
SACGHS
SACX
OBA Home

- Latest News
- *NIH Guidelines for Research Involving Recombinant DNA Molecules*
- Compliance Reminder
- Database on Human Gene Transfer Trials (GeMCRIS)
- Informed Consent in Gene Transfer Research
- Recombinant DNA Advisory Committee
  - Frequently Asked Questions (FAQs) Regarding Protocol Submission and RAC Review
  - RAC Roster (as of 9/12/2006)
  - Meetings and Conferences
  - Protocol List and Other Documents
  - Serious Adverse Event Reporting Template
- Institutional Biosafety Committees

Page Updated : 9/19/05

Questions?



BREAK!